Watch More Highlights

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses phase I/II findings from the MajesTEC-1 trial, which seems to confirm that teclistamab monotherapy induces deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Of note for advanced practitioners, this agent is a T-cell–redirecting, bispecific IgG4 antibody that targets both B-cell maturation antigen (BCMA) and CD3 receptors to induce the T-cell–mediated cytotoxicity of BCMA-expressing myeloma cells (Abstract 896).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.